Christopher M Heaphy1,2, Gaurav Gaonkar1, Sarah B Peskoe3, Corinne E Joshu2,3, Angelo M De Marzo1,2,4, M Scott Lucia5, Phyllis J Goodman6, Scott M Lippman7, Ian M Thompson8, Elizabeth A Platz2,3,4, Alan K Meeker1,2,4. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. University of Colorado School of Medicine, Aurora, Colorado. 6. SWOG Statistical Center, and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. 7. Moores Cancer Center, University of California, San Diego, California. 8. UT Health Science Center at San Antonio, San Antonio, Texas.
Abstract
BACKGROUND: Telomeres are repetitive nucleoproteins that help maintain chromosomal stability by inhibiting exonucleolytic degradation, prohibiting inappropriate homologous recombination, and preventing chromosomal fusions by suppressing double-strand break signals. We recently observed that men treated for clinically localized prostate cancer with shorter telomeres in their cancer-associated stromal cells, in combination with greater variation in cancer cell telomere lengths, were significantly more likely to progress to distant metastases, and die from their disease. Here, we hypothesized that shorter stromal cell telomere length would be associated with prostate cancer risk at time of biopsy. METHODS: Telomere-specific fluorescence in situ hybridization (FISH) analysis was performed in normal-appearing stromal, basal epithelial, and luminal epithelial cells in biopsies from men randomized to the placebo arm of the Prostate Cancer Prevention Trial. Prostate cancer cases (N = 32) were either detected on a biopsy performed for cause or at the end of the study per trial protocol, and controls (N = 50), defined as negative for cancer on an end-of-study biopsy performed per trial protocol (e.g., irrespective of indication), were sampled. Logistic regression was used to estimate the association between mean telomere length of the particular cell populations, cell-to-cell telomere length variability, and risk of prostate cancer. RESULTS: Men with short stromal cell telomere lengths (below median) had 2.66 (95% CI 1.04-3.06; P = 0.04) times the odds of prostate cancer compared with men who had longer lengths (at or above median). Conversely, we did not observe statistically significant associations for short telomere lengths in normal-appearing basal (OR = 2.15, 95% CI 0.86-5.39; P= 0 .10) or luminal (OR = 1.15, 95% CI 0.47-2.80; P = 0.77) cells. CONCLUSIONS: These findings suggest that telomere shortening in normal stromal cells is associated with prostate cancer risk. It is essential to extend and validate these findings, while also identifying the cellular milieu that comprises the subset of cells with short telomeres within the prostate tumor microenvironment.
RCT Entities:
BACKGROUND: Telomeres are repetitive nucleoproteins that help maintain chromosomal stability by inhibiting exonucleolytic degradation, prohibiting inappropriate homologous recombination, and preventing chromosomal fusions by suppressing double-strand break signals. We recently observed that men treated for clinically localized prostate cancer with shorter telomeres in their cancer-associated stromal cells, in combination with greater variation in cancer cell telomere lengths, were significantly more likely to progress to distant metastases, and die from their disease. Here, we hypothesized that shorter stromal cell telomere length would be associated with prostate cancer risk at time of biopsy. METHODS: Telomere-specific fluorescence in situ hybridization (FISH) analysis was performed in normal-appearing stromal, basal epithelial, and luminal epithelial cells in biopsies from men randomized to the placebo arm of the Prostate Cancer Prevention Trial. Prostate cancer cases (N = 32) were either detected on a biopsy performed for cause or at the end of the study per trial protocol, and controls (N = 50), defined as negative for cancer on an end-of-study biopsy performed per trial protocol (e.g., irrespective of indication), were sampled. Logistic regression was used to estimate the association between mean telomere length of the particular cell populations, cell-to-cell telomere length variability, and risk of prostate cancer. RESULTS:Men with short stromal cell telomere lengths (below median) had 2.66 (95% CI 1.04-3.06; P = 0.04) times the odds of prostate cancer compared with men who had longer lengths (at or above median). Conversely, we did not observe statistically significant associations for short telomere lengths in normal-appearing basal (OR = 2.15, 95% CI 0.86-5.39; P= 0 .10) or luminal (OR = 1.15, 95% CI 0.47-2.80; P = 0.77) cells. CONCLUSIONS: These findings suggest that telomere shortening in normal stromal cells is associated with prostate cancer risk. It is essential to extend and validate these findings, while also identifying the cellular milieu that comprises the subset of cells with short telomeres within the prostate tumor microenvironment.
Authors: Alan K Meeker; Wesley R Gage; Jessica L Hicks; Inpakala Simon; Jonathan R Coffman; Elizabeth A Platz; Gerrun E March; Angelo M De Marzo Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307
Authors: Bisera Vukovic; Paul C Park; Jaudah Al-Maghrabi; Ben Beheshti; Joan Sweet; Andy Evans; John Trachtenberg; Jeremy Squire Journal: Oncogene Date: 2003-04-03 Impact factor: 9.867
Authors: A M Joshua; E Shen; M Yoshimoto; P Marrano; M Zielenska; A J Evans; T Van der Kwast; J A Squire Journal: Prostate Date: 2010-10-28 Impact factor: 4.104
Authors: Christopher M Heaphy; Trisha M Fleet; Eric G Treat; Sang-Joon Lee; Anthony Y Smith; Michael S Davis; Jeffrey K Griffith; Edgar G Fischer; Marco Bisoffi Journal: Prostate Date: 2010-09-15 Impact factor: 4.104
Authors: Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald Journal: Cancer Cell Date: 2010-06-24 Impact factor: 31.743
Authors: Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Ian M Thompson; M Scott Lucia; Elizabeth A Platz; William D Figg; Ashraful Hoque; Ann Hsing; Marian L Neuhouser; Howard L Parnes; Juergen K V Reichardt; Regina M Santella; Cathee Till; Scott M Lippman Journal: Cancer Prev Res (Phila) Date: 2010-12
Authors: Eric G Treat; Christopher M Heaphy; Larry W Massie; Marco Bisoffi; Anthony Y Smith; Michael S Davis; Jeffrey K Griffith Journal: Urology Date: 2009-07-16 Impact factor: 2.649
Authors: Michael T Marrone; Corinne E Joshu; Sarah B Peskoe; Angelo M De Marzo; Christopher M Heaphy; Shawn E Lupold; Alan K Meeker; Elizabeth A Platz Journal: Clin Chem Date: 2018-12-05 Impact factor: 8.327
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Christopher M Heaphy; Michael C Haffner; Mindy K Graham; David Lim; Christine Davis; Eva Corey; Jonathan I Epstein; Mario A Eisenberger; Hao Wang; Angelo M De Marzo; Alan K Meeker; Tamara L Lotan Journal: Hum Pathol Date: 2020-05-07 Impact factor: 3.466
Authors: Christopher M Heaphy; Corinne E Joshu; John R Barber; Christine Davis; Reza Zarinshenas; Angelo M De Marzo; Tamara L Lotan; Karen S Sfanos; Alan K Meeker; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-08 Impact factor: 4.254
Authors: Sathyavathi ChallaSivaKanaka; Renee E Vickman; Mamatha Kakarla; Simon W Hayward; Omar E Franco Journal: Cancer Lett Date: 2021-10-29 Impact factor: 8.679
Authors: Benjamin A Rybicki; Sudha M Sadasivan; Yalei Chen; Ian Loveless; Nilesh S Gupta; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang L Tang Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-05-04 Impact factor: 4.090
Authors: Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Enrica Rampazzo; Silvia Giunco; Annarosa Del Mistro; Anna Menegaldo; Lorena Baboci; Monica Mantovani; Giancarlo Tirelli; Anita De Rossi Journal: Cancer Metastasis Rev Date: 2016-09 Impact factor: 9.264